NCT06132958: Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
- State
- Under way
- Phase
- Phase 3
- People
- 710 planned
- Started
- 6 Dec 2023
- Primary completion
- 10 Jan 2028
- Arms
- Sacituzumab tirumotecan
- Results
- None posted
- 15 Nov 2023: Trial registered
- 6 Dec 2023: Trial started